GFP‐SCFV: Expression and possible applications as a tool for experimental investigations of atherosclerosis |
| |
| Authors: | Aldacilene Souza Silva Dulcineia Saes Parra Abdalla Vitor Renaux Hering Mario José Politi Andrea Queiroz Maranhão |
| |
| Institution: | 1. Dept. of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Brazil;2. Dept. of Biochemistry, Inst. of Chemistry, University of Sao Paulo, Brazil;3. Dept. of Cell Biology, Molecular Immunology Laboratory, University of Brasilia, Brazil |
| |
| Abstract: | Experimental studies on atherosclerosis are crucial for investigating its pathophysiology, defining new therapeutic targets, and developing new drugs and diagnostic tools. Thus, many imaging markers have been developed and introduced in experimental studies. The main advantage of these new tools is that they allow the noninvasive diagnosis of atherosclerotic vascular disease. Here, we describe the cloning, expression, purification, and stabilization of a chimeric protein specifically designed to probe cells and tissues for the presence of LDL(?), a relevant marker of atherosclerosis. The DNA sequence that encodes the anti‐LDL(?) scFv, previously obtained from a hybridoma secreting an anti‐LDL(?) monoclonal antibody, was inserted into the bacterial vector pET‐28a(+) in tandem with a DNA sequence encoding GFP. The recombinant protein was expressed in high yields in E. coli as inclusion bodies. The applicability of GFP‐scFv was assessed by ELISA, which determined its affinity for LDL(?) and confocal microscopy, that showed macrophage uptake of the protein along with LDL(?). In conclusion, our data suggest that the anti‐LDL(?) GFP‐scFv chimeric protein could be useful in studies on atherogenesis as well as for developing diagnostic tools for atherosclerosis. © 2014 American Institute of Chemical Engineers Biotechnol. Prog., 30:1206–1213, 2014 |
| |
| Keywords: | fluobodies atherosclerosis electronegative LDL recombinant protein refolding |
|
|
